|Main uses||Mucopolysaccharidosis II (MPS-II)|
|Side effects||Rash, fever, headache, high blood pressure, flushing|
|Typical dose||0.5 mg/kg q 1 week|
Idursulfase, sold under the brand name Elaprase, is a medication used to treat mucopolysaccharidosis II (MPS-II, Hunter syndrome). It is given by gradual injection into a vein. It is used long term. Effects on life expectancy and quality of life is unclear.
Common side effects include rash, fever, headache, high blood pressure, and flushing. Other side effects may include shortness of breath, heartburn, chest pain, and anaphylaxis. It is a form of lysosomal enzyme known as iduronate-2-sulfatase and is made by recombinant DNA technology.
Idursulfase was approved for medical use in the United States in 2006 and Europe in 2007. In the United States it costs about 475,000 USD to treat a 35 kg person for a year. In the United Kingdom this amount costs £310,000.
It is given at a dose of 0.5 mg/kg once per week.
- "Idursulfase Monograph for Professionals". Drugs.com. Archived from the original on 2 December 2021. Retrieved 25 November 2021.
- "Elaprase". Archived from the original on 11 December 2021. Retrieved 25 November 2021.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1116. ISBN 978-0857114105.
- "Idursulfase" (PDF). September 2009. Archived (PDF) from the original on 15 April 2021. Retrieved 25 November 2021.
- "Idursulfase Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 25 November 2021.